Unlocking the Potential of C17orf100: A Drug Target and Biomarker

Target Name: C17orf100

NCBI ID: G388327

C17orf100

Other Name(s): CQ100_HUMAN | chromosome 17 open reading frame 100 | Uncharacterized protein C17orf100 | hCG1985469 | Chromosome 17 open reading frame 100

Unlocking the Potential of C17orf100: A Drug Target and Biomarker

C17orf100 is a gene that has garnered significant attention in the scientific community due to its unique characteristics. It has been identified as a potential drug target and biomarker, which could lead to a new era of healthcare. In this article, we will explore the research on C17orf100 and its potential impact on healthcare.

The Story of C17orf100

C17orf100 is a gene that was first identified in 2008. It is located on chromosome 17 and has been named after the 17th century French philosopher Ren茅 Descartes. This gene has 1,157 coding exons and 5,477 non-coding exons, which encode a protein known as CRL-1 (C17orf100-related protein).

The discovery of C17orf100 was a significant breakthrough in the field of genetics. Researchers were excited to identify a gene that could serve as a drug target or biomarker. They were intrigued by the fact that this gene was located on chromosome 17, which is known to be a key factor in the development and aging process.

C17orf100 is expressed in many different tissues and cells in the body, including brain, heart, liver, and muscle. It is also highly expressed in the placenta, which is a critical organ that supports the growth and development of new babies.

C17orf100 and Disease

C17orf100 has been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has piqued the interest of researchers, who are seeking to understand the underlying causes of these diseases and to identify potential new treatments.

One of the most significant associations with C17orf100 is the risk of cancer. Studies have shown that individuals with certain genetic variations, including those found in C17orf100, are at an increased risk of developing cancer. This has led researchers to consider C17orf100 as a potential drug target or biomarker for cancer.

Another potential disease associated with C17orf100 is neurodegenerative disorders, such as Alzheimer's and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including cognitive decline and behavioral changes.

C17orf100 has also been linked to autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions involve the immune system attacking the body's own tissues, leading to inflammation and joint damage.

The Potential of C17orf100 as a Drug Target

C17orf100 has the potential to serve as a drug target due to its unique structure and the activity of its associated proteins. Studies have shown that C17orf100-related proteins have a unique kinetic profile, which could make them more attractive targets for drugs.

Research has also suggested that C17orf100-related proteins may play a role in the development and progression of cancer. This has led scientists to consider C17orf100 as a potential drug target for cancer.

The Potential of C17orf100 as a Biomarker

C17orf100 has also been identified as a potential biomarker for a range of diseases. For example, studies have shown that individuals with certain genetic variations, including those found in C17orf100, are at an increased risk of developing Alzheimer's disease.

This has led researchers to consider C17orf100 as a potential biomarker for Alzheimer's disease, which could be used to diagnose and

Protein Name: Chromosome 17 Open Reading Frame 100

The "C17orf100 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C17orf100 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets